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impaired verbal and nonverbal communication and socialization owing to neurodevelopmental
abnormalities. The most recent estimate for the prevalence of autistic disorders is about 1% on a
global scale. Etiology of autism is multifactorial and multidimensional that makes therapeutic inter-
vention even harder. Heterogeneity of genetic factors, oxidative stress, autoimmune mechanism,
and epigenetic mechanisms complicate the nature of pathogenesis of the disease. Nutraceutical
approach to treat this disease is a promising strategy, especially in some areas, it is more attractive
than others. This review critically analyzes the roles of vitamins and cofactors, dietary modiﬁcations
and gut abnormalities, probiotics and prebiotics, phytochemicals, and environmental factors in
order to determine the state of evidence in nutraceutical-based autism management practices. This
article presents a systematic review of randomized- and placebocontrolled trials to examine the
evidence supports the use of autism nutraceuticals. The results will be discussed in the light of all
relevant evidence generated from other clinical and exploratory studies.
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Autistic spectrum disorders (ASDs) are increasingly prevalent
neurodevelopmental behavioral syndromes of impaired verbal
and nonverbal communication and socialization skills among
234 A.S. Alanazichildren. Individuals with ASDs suffer from impairments in
social interactions; in language, communication and imagina-
tion; and in the range of interests and activities. In the last
few decades, reﬁnements of diagnostic techniques have led to
the differentiation and variation in traditional use of the term
autistic disorder to include autism, Asperger’s syndrome,
Rett’s syndrome, and childhood disintegrative disorder. The
ASD onset occurs during the ﬁrst three years of life and has
a gender bias with a ratio of 5 males to 1 female (World Health
Organization, 1992; Fombonne, 2002; Rapin, 2002; Tonge and
Brereton, 2011; Center for Disease Control). Common comor-
bidities associated with ASDs include gastrointestinal disease
and dysbiosis, autoimmunity and mental retardation (Bolte
and Poustka, 2002; Sweeten et al., 2003; Buie et al., 2010).
One of 88 children in USA develops any form of ASD, and
global prevalence is about 1% (Muhle et al., 2004). In Saudi
Arabia, there were 42,500 conﬁrmed cases of autism in the year
2002 (Al-Yafee et al., 2011). In reality, many cases remain
undiagnosed in the Arabian Peninsula as suggested by Mosta-
fa et al and other authors as well, who indicate autism preva-
lence of 1.4 cases per 10,000 children in Oman and 2.9/10,000
in United Arab Emirates (Mostafa, 2011). About 22–30% of
children suffering from ASDs also develop seizures without
exhibiting underlying pathology. Moreover, about 25% chil-
dren with ASDs show hypersensitivity-like symptomatology
(Theoharides and Zhang, 2011).
Among the ASDs, autism is particularly a severe syndrome
characterized by the impairment of reciprocal social interac-
tions and communication development along with extremely
restricted and repetitive stereotyped behaviors and corre-
sponding motivational proﬁles (American Psychiatric Associa-
tion, 2000). Among the autistics, about 85% suffer from
idiopathic autism or primary autism where the exact cause of
the disease remains unknown. On the other hand, symptomatic
or secondary autism where the causative factor can be deter-
mined exists only in 15% of the cases (Sakai et al., 2011).
The exact etiology of autism is unclear, and because of the
fact that its pathogenesis starts quite early during embryonic
development preventive measures are hard to take. Multifacto-
rial and multidimensional causation of autism include genetic
basis and heterogeneity, gastrointestinal pathology, autoim-
mune complications, inﬂammation, high level of oxidative
stress, decreased ability of the body to detoxify toxins, de-
creased function of mitochondria, and iatrogenic causes such
as vaccinations and food additives. Thus, a number of factors
contribute to the pathogenicity of ASDs, of which many are
interactive. Autoimmunity to central nervous system exists in
many autistic patients (Al-Yadhi and Mostafa, 2011). Oxida-
tive stress from reactive oxygen species is a substantial causa-
tive factor for the development and severity of ASDs (Al-
Ayadhi et al., 2012).
Genetic studies involving twins, families and genetic associa-
tions have revealed a strong genetic correlation in the etiology of
autism (Muhle et al., 2004; Folstein and Piven, 1991; Campbell
et al., 2006). Heritability in autism exists in as high as 90% of
cases. Moreover, twin studies have revealed monozygotic con-
cordance rate of 36–96% as against 0–27% in dizygotic twins
(Bakare et al., 2011). Furthermore, genetic heterogeneity behind
ASDs is a crucial aspect of their etiology. Also, the potential role
of X-linked inheritance has also been demonstrated (Liu et al.,
2001; Glessner et al., 2009). Environmental factors also have
potentials to contribute signiﬁcantly to autistic pathogenesis,which besides others, also involve epigenetic mechanisms
(Folstein and Piven, 1991; Kinney et al., 2008; Kubota et al.,
2012) and even there are some theories from an evolutionary
perspective as well (Ploeger and Galis, 2011). Recent studies in
animals as well as in humans have identiﬁed a vital aspect of
gene-environment interaction. An individual with a particular
genetic makeup is far more vulnerable to any behavioral disor-
der such as autism if exposed during the perinatal period to an
environmental pathogen or stress (Meaney and Szyf, 2005;
Caspi and Mofﬁtt, 2006; Rutter et al., 2006).
1.1. Nutraceuticals and autism
Food is no longer valued from a nutritional point of view only
rather it is equally valuable from a health perspective. The use
of food or food products in disease prevention or health pro-
motion is an emerging trend that has given rise to the concept
of ‘nutraceuticals’. Nutraceuticals is a term ﬁrst coined in 1989
by the US Foundation for Innovation in Medicine (FIS). FIS
deﬁned nutraceuticals as ‘‘any substance that is food or a part
of food and provides medical or health beneﬁts, including the
prevention and treatment of disease’’ (Brower, 1998; Alissa
and Ferns, 2012). General forms of nutraceuticals consist of
dietary supplementation (products that supplement the diet
such as vitamins, minerals, amino acids, and herbal substances
in any composition). Moreover, the term nutraceuticals go a
level up in the sense that it also helps in the prevention or treat-
ment of disease by modifying conventional foods like sole meal
as against dose based dietary supplements (Kalra, 2003;
Pandey et al., 2010).
The use of nutraceuticals in autism management can create
a successful integrative model with current treatment to
achieve desired results. Nutraceuticals offer several promising
beneﬁts that may include promoting healthy gut and lowering
body burdens of toxins, reducing excitotoxicity, improving
antioxidant capacity, enhancing immunomodulatory systems
and minimizing stress and environmental contamination/
hazards (Defeat Autism Now (DAN) Project, 2002). Indeed,
in 1995, a campaign (Defeat Autism Now) was started by a
collaborative network including scientists and physicians with
support from parents of autistic children and community. Be-
sides boosting passion for research and practice, to its favor,
go a number of scientiﬁc publications speciﬁcally intervention
protocols that guide physicians to manage autistic patients
(Levy and Hyman, 2008). Nutraceuticals can signiﬁcantly ad-
vance autism management in a situation where etiological
complexity and limitations in earlier interventions hinder ther-
apeutic regimens. Because of their potential beneﬁts, a number
of companies have produced several compositions of nutraceu-
ticals available in the market, and there is anecdotal evidence
for their efﬁcacies in autistic as well as patients with similar
neurological complications. This paper reviews research-based
ﬁndings about various factors of nutraceuticals in relation to
their potentials in autism treatment by consulting the most rel-
evant literature available on this subject.2. Method
In this systematic analysis, literature was gathered from Pub-
med (US National Library of Medicine) /PsycINFO/CINAHL
databases using search keywords with restriction to articles
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related (autism, autistic spectrum disorders) and nutraceuticals
related (nutraceuticals, vitamins, multivitamin/minerals, prebi-
otics, probiotics, biopterins, gluten, casein, diet, fatty acids,
phytochemicals, and toxic). Then disease related terms com-
bined with nutraceuticals related terms, and the result was re-
stricted to control trials. Database suggested corroborations
were also examined. Reference list of articles was also explored
in search of relevant articles. This review considered only jour-
nal articles and proceedings. Search criteria were randomized
controlled trial (RCT) and placebo controlled trial (CT) car-
ried out and published in relevance with autism nutraceuticals
during 1987–2012. Only eleven research publications could be
identiﬁed which fulﬁlled the search criteria. Finally, the sys-
tematic review included only eleven selected articles after com-
pleting standard steps of identiﬁcation, selection, analysis,
synthesis and compilation. In order to assess the most recent
position on the subject, currently proceeding RCTs were also
identiﬁed, mainly from US National Institute of Health data-
base (clinicaltrials.gov). For more vigorous discussion, other
signiﬁcant and relevant research studies were also included.
Interrater reliability was sufﬁciently strong to promote the
overall process of analysis and manuscript preparation.
3. Results
This review of literature has recognized eleven studies report-
ing either RCT or CT conducted to evaluate the effectiveness,
safety and tolerability of several nutraceutical factors for treat-
ing one or more forms of ASD. These studies are summarized
in Tables 1 and 2 which provide information on intervention,
outcome measures, outcome and fundamental limitations.
Overall, these interventional studies examined treatment possi-
bilities of multivitamins/minerals (2 RCTs), L-carnitine (2
RCTs), dietary fatty acids (2 RCTs), gluten- and casein-free
diet (1 RCT), biopterins (2 CTs), ascorbic acid (1 CT), and
prebiotics (1CT). Population size of these studies ranged be-
tween 12 and 141 participants and was strongly male biased.
Age range of the participants was 3–17 years. In these studies,
the most usual dependent variables for interventions were
clinical global impressions (CGI), autism treatment evaluation
checklist (ATEC), pervasive development disorder behavior
inventory (PDDBI), childhood autism rating scale (CARS),
Aberrant behavior checklist (ABC), Leiter international per-
formance scale (LIPS), Peabody picture vocabulary tests
(PPVT), expressive vocabulary test (EVT), and social respon-
sive scale (SRS). Tolerability measurements conducted by
using frequency and intensity of side effects rating (FISER),
global rating side effects burden (GRSEB), and patient report
to the incidence of side effect (PRISE). Some studies also used
biological indicators for measuring a change and carried out
laboratory testing.
All these studies are bound to various limitations, therefore,
are unable to reveal conclusive evidence. Study population size
remains the most serious limitation of these studies with an
average of about 40 participants, which is inadequate for reli-
able statistical analysis. In some trials, the duration of inter-
vention appears to be shorter which is also recognized by the
researchers. Inconsistencies in results of intervention duration
are also evident e.g., Amminger et al. (2007) ﬁnd improvement
in autism symptoms with a 6 week treatment of omega-3 fattyacids (EPA and DHA) while Bent et al. (2011) after treating
for 12 weeks with these dietary fatty acids ﬁnd no signiﬁcant
difference. Evaluation of this intervention in ongoing RCTs
is being conducted from 8 to 24 weeks. Dose optimization
and other medication intake controls were also reported as
limitations that might have played roles altering the results
in a couple of studies. Another limitation was the diagnosis
of the actual condition which has been reported by at least
one study.
As Table 1 summarizes, RCTs which examined the effect of
multivitamin-mineral supplementation reported signiﬁcant
beneﬁts of this intervention to ASD patients. Though in the
study of Adams and Holloway (Adams and Holloway, 2004)
population size was small (20 participants), in Adams et al.
(2011) the number of participants was relatively large (141 par-
ticipants) but the age of the participants ranged between 3 and
60. Two RCTs have evaluated the effectiveness of levocarni-
tine in ASD patients. Ellaway et al. (1999) reported improve-
ment in hand apraxia, which was seen more in girls, as well
as patient well-being beneﬁts. On the other hand, Geier et al.
(2011) reported improvement in autism symptoms measured
by ATEC, CARS and CGI scores, though study population
size was small in both of these RCTs (35 and 34 respectively).
Two RCTs are identiﬁed that examined the efﬁcacy of omega-
3 fatty acids in ASD patients. Amminger et al. (2007) studied
children with ASD and found the intervention beneﬁcial as it
improved symptoms by reducing hyperactivity and stereotypy
while Bent et al. (2011) found no signiﬁcant difference of treat-
ment in treated and control groups. Again in both studies, the
population size was small (17 and 24, respectively). (Knivsberg
et al., 2002) conducted a RCT to evaluate the effect of gluten-
and casein-free diet for one year in twenty autistic children and
reported signiﬁcant improvement in autism symptoms
reduction.
As Table 2 summarizes, two CTs examined the effects of
tetrahydrobiopterin treatment. Naruse et al. (1987) with a
study population size of 84 participants found this intervention
effective in patients with infantile autism while Danfors et al.
(2005) with 12 participants (autistic children) reported a small
but statistically insigniﬁcant effect. In a CT designed to assess
the efﬁcacy of ascorbic acid, Dolske et al. found signiﬁcant
improvement in symptom reduction along with improvement
in sensory and motor scores with a study population of 18
autistic children (Dolske et al., 1993). Parracho et al. (2010)
conducted a CT to evaluate the effectiveness of prebiotics
WCFS1 and found it signiﬁcantly beneﬁcial in treating autism.
Table 3 summarizes currently proceeding RCTs in relation
to many autism nutraceutical aspects. Major aspects of these
RCTs include vitamins/minerals (7 studies), dietary fatty acids
(5 studies), levocarnitine, creatine, cysteine-rich diet and glu-
ten/casein-free diet (one study each). Range of the participants
in these RCTs is 16–141.
4. Discussion
Though there is scarcity of control trials in the ﬁeld of autism
nutraceuticals, impetus to conduct RCTs is sufﬁcient. There
are a number of studies which depict a positive role of
vitamins/minerals-based nutraceuticals in treating ASDs. In
a case-control study comparing two autism management strat-
egies, the ﬁrst group of 44 autistic patients, with an age range
Table 1 Summary of randomized controlled trials related to autism nutraceuticals.
Study Aspect Number of subjects Intervention Primary outcome
measures
Secondary outcome
measures
Major ﬁndings Limitations
Adams and
Holloway (2004)
Multivitamin/
mineral supplements
in ASD patients
20 children (3–
8 years of age), 18
boys and 2 girls
A gradual increment
of multivitamin/
mineral suspension
(spectrum support II
to III) to a
maximum dose of
3 ml/5 lb body
weight for 3 months
Global impression
survey (mothers
ﬁlled questionnaire)
Vitamins and
metabolite levels
Signiﬁcant
improvements in
sleep and gut
function
Small study size,
behavioral
assessment
through
parental
assessment only.
Adams et al.
(2011)
Multivitamin/
mineral supplement
in patients with
autism
141 (3–60 years of
age) 125 males and
16 females
A gradual increment
of multivitamin/
mineral suspension
during 3 month
treatment period
ATEC, PDDBI,
parental global
impressions-revised
(PGI-R), severity of
autism scale
Metabolic indicators Signiﬁcant
improvement in
reduction of autism
symptoms and
metabolic
indicators.
Shorter study
period. Placebo
constitution
might have
aﬀected the
results. Some
subjects were
also on other
medication
Ellaway et al.
(1999)
L-Carnitine
treatment to autistic
(Rett syndrome)
patients
35 patients L-Carnitine
treatment for
8 months
Rett syndrome
motor behavioral
assessment, hand
apraxia
Patient well-being
index
Improvement in
patient well-being
and hand apraxia
specially in girls
Poor
identiﬁcation of
predictors of
clinical
improvement
due to a small
study size and
duration
(8 week)
Levy and
Hyman (2008)
L-Carnitine
supplement to ASD
patients
34 children (30 boys
and 4 girls)
L-Carnitine at a dose
of 50 mg/kg bw/day
twice daily for
3 months
CARS, ATEC, CGI,
hand muscle test
Lab testing, FISER,
GRSEB, PRISE
Signiﬁcant
improvement in
CARS, CGI and
ATEC scores
Too small study
size to observe
statistical
signiﬁcance,
optimal dosing
may not have
been achieved
Amminger et al.
(2007)
Omega-3 fatty acids
supplement in
autistic children
13 (5–17 years of
age)
1.5 g/day of omega-3
fatty acids (0.84 g/
deicosapentaenoic
acid (EPA) + 0.7 g/
daydocosahexaenoic
acid (DHA) for six
weeks
ABC subscales None Improved symptoms
(hyperactivity and
stereotypy)
Small size of the
study
population
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The role of nutraceuticals in the management of autism 237of 2–28 years, were recommended to take micronutrient
supplement containing 14 vitamins, 16 dietary minerals, 3 ami-
no acids, and 3 antioxidants without any medication for aut-
ism. On the other hand, the second group of 44 autistic
children were recommended conventional medication without
supplementation. Patients in both groups improved, but the le-
vel of improvement was signiﬁcantly greater in micronutrient
recommended group than in conventional medication group
(Mehl-Madrona et al., 2010).
Women who used vitamin supplements during periconcep-
tional period had a lower risk of having autistic children. In a
population-based case-control study, mothers of 288 autistic
children were less likely to report vitamin intake 3 months be-
fore and during the ﬁrst month of conception compared to the
mothers of normal children of the study (Schmidt et al., 2011).
Similarly, in a preliminary observatory study, administration
of vitamin B12 and glutathione along with low fructose and
food additive/color organic diet of ten children (4–10 years
of age) for 3–6 months signiﬁcantly improved social interac-
tion, concentration, writing, language, and behavior (Patel
and Curtis, 2007). A meta-analysis of 18 studies revealed that
supplementation of vitamin B6 especially in combination with
magnesium improved the health conditions of autistic chil-
dren, though it did not fully cure the disorder (Kidd, 2002;
Cornish and Mehl-Madrona, 2008). Autistic children most
usually have low levels of vitamin B12 and folate (Ali et al.,
2011).
Though these RCTs (Adams and Holloway, 2004; Adams
et al., 2011) support the general notion that multivitamins/
mineral supplementation remains effective in reducing the
symptoms of ASD, there remain several matters to be further
evaluated e.g., Adams et al. (2011) suggested a larger study
population size for more reliable statistical analysis. Moreover,
studies of individual vitamins and other cofactors may also
generate useful evidence.
Almost all autistic patients suffer from essential fatty acids
deﬁciency especially omega-3 fatty acids (Vancassel et al.,
2001). In an Internet based survey addressing parents of
the autistic children, 43% families avail vitamin supplementa-
tion and about 28% families supplement omega-3 fatty acid
in the diet of autistic children (Richardson, 2004). Whereas,
in a special group of 187 autistic children (with verbal aprax-
ia), a combinational supplementation of vitamin E and ome-
ga-3 fatty acids produced dramatic improvements in speech,
imitation, eye contact, coordination, behavior and sensory
function (Morris and Agin, 2009). However, a conclusive
beneﬁcial effect of omega-3 fatty acid supplementation has
not been achieved in RCTs (Amminger et al., 2007; Bent
et al., 2011). After reviewing studies concerning the effect
of omega-3 fatty acids on behavior and brain function,
Wilczynski-Kwaitek et al. (2009) concluded that data gath-
ered so far are insufﬁcient and lack standardization modali-
ties. Moreover, they lack intermediary as well as endpoint
omega 6/3 ratios in plasma lipids in both epidemiological
and intervening studies, which warrants a better-designed
research in this ﬁeld.
Autistic children especially those younger than six years of
age excrete copious amount of biopterins (cofactor molecules
necessary for the biosynthesis of catecholamine and several
other pathways) in urine extraordinarily. Cerebrospinal ﬂuid
concentration of tetrahydrobiopterin tends to be 42% less in
autistic children as compared to normal children (Tani et al.,
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238 A.S. Alanazi1994). This is presumably due to depletion of this cofactor in
over-activated immune and inﬂammatory processes (Castellani
et al., 2009). Results of the CT conducted by Naruse et al.
(1987) revealed signiﬁcant beneﬁts of tetrahydrobiopterin
treatment to autistic children and several other studies of this
group strengthen their evidence that reveals that as much as
41–64% of 300 (mild to severe) Japanese autistic children
showed encouraging improvement in symptoms upon treat-
ment with tetrahydrobiopterin (Frye et al., 2010).
Naurse et al. (1989) have reported that autistic children un-
der 5 years of age were found to be more responsive to positive
effects of tetrahydrobiopterin than their counterparts over ﬁve.
Moreover, CT conducted by Danfors et al. (2005)has demon-
strated improvement in social interaction in tetrahydrobiopter-
in treated autistic children positively correlates with
intelligence quotient of the patients. Frye et al. (2010) after
reviewing previous relevant studies expressed that treatment
of autistic children with tetrahydrobiopterin has been associ-
ated with beneﬁcial effects in language skills, eye contact,
sociability, communication and stereotyped behaviors. Also,
they stressed on the need for carrying out larger double-blind
placebo controlled studies as, so far, data has generated mainly
from open labeled potentially biased studies. Furthermore, he
recommended studying biological effects along with behav-
ioral outcomes that will improve the understandings of the role
of biopterins in ASDs. Moreover, standardization of dose pat-
terns can also help in comparing multiple trials in meta-
analyses.
As the autistic children remain unable to catabolize prop-
erly casein (milk protein) and gluten (wheat protein) Kidd
(2002), Elder et al. (2006), this results in the production of toxic
peptides possessing opioid activity capable of crossing the
blood brain barrier to contribute in pathogenesis and severity
of ASDs (Vojdani et al., 2004). Lucarelli et al. (1995) reported
beneﬁcial effects of casein-free diet in about two third of the 36
subjects who were fed cow milk free diet for 8 weeks. Cornish
(1998) noticed that 13 of 17 autistic children were consuming
excessive amount of milk while intake of many nutrients was
lower than normal, when he interviewed the parents of autistic
children.
After reviewing a considerable number of studies, Knivs-
berg et al. (2001) revealed that autistic children who were fed
on casein and gluten-free diets grew better than their control
counterparts. However, Cornish, 2002 could not ﬁnd any sig-
niﬁcant difference between casein and gluten-free autistic chil-
dren and the control group, though, the sample size was small,
results were based on a postal survey, and researcher suggested
a longitudinal study to evaluate this dietary intervention.
Mulloy et al. (2010) after systematically reviewing 14 studies
pertaining to evaluation of effectiveness of gluten- and case-
in-free diet in ASD patients, concluded that the evidence to
support this intervention as an autism treatment strategy is
weak. Findings from similar studies suggest that various
interactive factors pertaining to diet implementation, gastroin-
testinal status and immune factors appear to play a role in
determining diet responder from diet nonresponder children
with ASDs (Pennesi and Klein, 2012). This ﬁnding suggests
that genetic variations in the etiological factor may also affect
the uniformity of this intervention.
High dose probiotics recommendations (e.g., containing
Biﬁdobacteria and Lactobacilli) constitute a serious therapeutic
strategy for autism patients as such a treatment enhances the
Table 3 Currently proceeding randomized controlled trials in the area of autism nutraceuticals.
Trial Identiﬁer Title Intervention Primary outcome
measures
Secondary outcome
measures
Enrolled subjects Status Executer
NCT00273650 Eﬃcacy study of subcutaneous
methyl-B12 (methylcobalamin) in
children with autism
Methylcobalamin (25,000 lg/ml),
at 64.5 lg/kg or saline placebo
s.c. once every 3 days for 6 weeks
then subjects cross over for
another 6 weeks. After 12 weeks,
open label treatment once every
3 days for 6 months.
Clinical global
impression (CGI)
scale
Neuropsychological
test (NEPSY),
Aberrant behavior
check list (ABC),
childhood autism
rating scale (CARS),
etc.
35 Complete University of
California, Davis
NCT01230359 Early nutritional in patients with
autism spectrum disorders
Pyridoxine hydrochloride 2.5 g/
day for subjects weighing up to
27 kg and 5 g/day for greater
than 27 kg for 12 weeks
Improvement in
blood parameters
Developmental
assessments for ASD
40 Complete Hamad Medical
Corp. /Qatar
University/
Heidelberg Uni.
NCT00467818 Omega-3 fatty acids in the
treatment of children with ASDs
Omega 3 fatty acid treatment
starts with low doses and based
on the weight of individual
dosage is increased biweekly.
CGI, ABC,
Vineland Adaptive
behavior scale
(VABS)
Overt aggression
scale, parental stress
index
60 Ongoing University of
Medicine and
Dentistry New
Jersey/NCCAM
NCT01602016 A folinic acid intervention for
autism spectrum disorders
12 week folinic acid treatment at
1 mg/kg/day for 2 week and then
2 mg/kg/day for 10 weeks. This
follows open label extension of
both these patterns for 22 weeks
Language
improvement
(CELF index)
Improved
stereotyped behavior
and improved social
skills
130 Ongoing Arkansas Uni. /
Arkansas Children
Hospital Research
Institute
NCT01154894 Dietary fatty acid improve social
impairment in autism spectrum
disorders
Subjects over 12 years of age
received 6 capsules of Aravita
(arachidonic acid and
docosaheaenoic acid) and
subjects under 12 received 4
capsules for 16 week period
ABC Social
responsiveness scale
(SRS)
13 Complete Ashiya University
NCT00672360 Folate rechallenge Folic acid treatment at dose
7.6 mg orally twice a day for
4 weeks.
ABC, PDDBI Plasma folate
metabolite levels and
site speciﬁc DNA
methylation
16 Ongoing Baylor College of
Medicine
NCT01147575 Eﬀects of creatine
supplementation in Rett
syndrome
200 mg creatine monohydrate/
kg/day as three doses per day for
six months. Treated vs placebo
group switch over after 4 week
gap.
Global DNA
methylation in
serum
Metabolic markers
of methylation cycle
21 Complete Medical University
of Vienna
NCT01225198 Vitamin/mineral supplement for
children and adults with autism
A broad spectrum multivitamin/
mineral supplement for 12 weeks
Oxidative stress
(levels of plasma
nitrotyrosine)
Parent global
impressions (PGI-R)
143 Complete Arizona State
University/Autism
Research Institute
NCT00090428 Diet and behavior in young
children with autism
Gluten- and casein-free diets for
18 weeks
Safety/eﬃcacy of
gluten- and casein-
free diet
None 30 Unknown National Institute of
Mental Health
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Table 3 (Continued)
Trial Identiﬁer Title Intervention Primary outcome
measures
Secondary outcome
measures
Enrolled subjects Status Executer
NCT01366859 Nutritional intervention in
children with autism using
protein (immunocal) impact on
core areas of behavior
Immunocal (cysteine-rich whey
protein) treatment at a dose of
0.5 g/kg for less than 18 kg
weight of subjects and 10 g/day
for over 18 kg weight subjects for
three months.
Behavioral analysis
(severity in autism
symptoms,
communication, and
development)
Safety analysis
(adverse events
recording)
60 Ongoing Nova Southeastern
University/
Immunotec Inc.
NCT01248728 Omega-3 fatty acids for
treatment of young children with
autism
Omega-3 fatty acids treatment
(ﬁrst 2 weeks at a dose of
1.875 ml/day and later 3.75 ml/
day) for 24 week
PDDBI CGI, VABS,
preschool language
scale-4 (PLS-4)
40 Ongoing University of
Toronto/
EvdokiaAnagnostou
NCT01039792 Trial of methyl-B12 on
behavioral and metabolic
measures in children with autism
Treatment of methyl-B12
(methylcobalamin) at a dose of
75 lg/kg s.c. once every three
days for 8 weeks.
CGI-I None 50 Ongoing University of San
Francisco/
University of
California, Davis
NCT01248130 Omega-3 fatty acids
monotherapy in children and
adolescents with ASDs
Treatment of 3 capsules per day
(1500 mg omega-3 fatty acids) for
12 weeks.
SRS, CGI-PDD None 40 Ongoing Massachusetts
General Hospital
NCT00811083 Dimercaptosuccinic acid
(DMSA) treatment of children
with autism and heavy metal
toxicity
4 month treatment of 3 doses of
10 mg DMSA/kg bodyweight for
3 days and then 11 days oﬀ
Safety and eﬃcacy Excretory
measurements
80 Complete Southwest College
of Naturopathic
Medicine
NCT00376194 Mercury chelation to treat
autism
Not mentioned Improvement in
social reciprocity
Language skills 120 Complete National Institute of
Mental Health
ISRCTN 4273114 A clinical trial of levocarnitine to
treat ASD
L-carnitine at a dose of 50 mg/
kg bw/day for 3 months
CARS, CGI, ATEC,
Hand muscle test
Treatment
adherence
measurement, side
eﬀects, laboratory
tests
30 Complete Autism Research
Institute
JPRN-UMIN 000002650 Eﬀects of vitamin B6 in children
with autism
Pyridoxal 5-phosphate oral dose
of 5 mg/kg/day for ﬁrst 2 weeks
followed by a double dose for
2 weeks and switchover
CGI, PPD Autism
Society Japan
Rating scale
ABC, social
maturity scale
100 Ongoing Tohoku University
School of Medicine
EUCTR2007–006444-21-ES Eﬀect of 8-week omega-3 fatty
acid treatment on oxidative
metabolism in patients with ASD
Oral administration of omega-3
fatty acid capsules (350 mg/ml)
Biological testing CGI, ABC, SRS Not given Ongoing Biomedical
Research
Foundation of
Gregorio Maranon
Hospital
2
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Figure 1 A trend of increasing interest of researchers in
conducting RCTs related to autism nutraceuticals.
The role of nutraceuticals in the management of autism 241integrity of gut mucosa (Brudnak, 2002) and have been found
to produce beneﬁcial effects in alleviating the symptoms of
autism (Douglas and Sanders, 2008). Such evidence is further
supported by one of the CTs identiﬁed in this study (Parracho
et al., 2010). Unwanted yeast species, such as Candida, cannot
grow in the presence of normal gut ﬂora. Invitro, the addition
of tetracycline (antibiotic) to the medium increased the growth
of this yeast species, but Candida was reduced in growth when
a probiotic species, Lactobacillus plantarum was added to med-
ium (Payne et al., 2003).
Probiotics constituting Lactobacilli and Biﬁdobacteria are
also capable of transforming toxic mercury compounds into
metabolites excretable in feces, and thus can also play a vital
role in treating autism (Brudnak, 2002). Autistic patients pos-
sess weak detoxiﬁcation capabilities. Therefore, exposure to
environmental toxicants can be far more hazardous to them
(Curtis and Petel, 2008). For this reason, many practitioners
prescribe chelating drugs for heavy metal contamination in
autistic patients. Several chelating agents are used includ-
ing dimercaptosuccinate (DMSA), ethylene diaminetetraacetic
acid (EDTA), dimercaprol, and penicillamine. Research stud-
ies acknowledge beneﬁts of chelation therapy e.g., DMSA
has proven its efﬁcacious potentials in autistic children (Adams
et al., 2009) though there are a few occasional reports of fatal-
ities following chelation therapy with EDTA (Brown et al.,
2006). Some natural products such as Chinese parsley (Corian-
drumsativum) extract which binds metals like lead (Aga et al.,
2001) can offer promising prognosis.
Flavonoids like luteolin are also found to inhibit autism like
symptoms in mice (Parker-Athill et al., 2009). In an open case
series noncontrolled trial, a ﬂavonoid supplement composing
of luteolin, quercetin and rutin in a liposomal formulation of
olive kernel oil was evaluated in 37 4–14 years old autistic chil-
dren and was found beneﬁcial in improving gastrointestinal
and allergy symptoms, eye contact condition, and social inter-
actions (Theoharides et al., 2012). However, many ﬂavonoids
possess antithyroid properties and can also alter normal hypo-
thalamic-pituitary axis. Thus, excessive use of ﬂavonoids dur-
ing pregnancy can adversely affect fetal brain development
(Roman, 2007). Therefore, it is a hazardous class of nutraceu-
ticals for neurodegenerative disorders like ASDs. Diet can be
adjusted with required ﬂavonoid depending on the patient’s
etiopathogenic factors, conditions and requirements.
Though, the roots of autism cannot be eliminated, the trig-
gering factors can be ameliorated. Therefore, interventions
involving dietary manipulations are now increasingly used in
treating autism spectrum disorders, and so far results are
encouraging. Nutraceuticals for autism treatment need careful
execution protocols as every autistic patient is different from
other autistic patient. Moreover, it is not an easy task to ad-
dress etiological heterogeneity of this symptomatology with se-
vere neurological disorder so generally (Shattock and
Whiteley, 2000).
Prevalence of autism is rather increasing, and with the
development of better diagnostic techniques, groups and sub-
groups are identiﬁed that should be used to classify nutraceu-
ticals of autism, as well. Pregnant women’s nutrition and
infant nutrition are the most valuable targets for a preventive
nutraceutical strategy as the nutritional, and environmental
factors exploit critical periods of development to alter meta-
bolic and endocrine imprinting and associated neural circuitry.Furthermore, physiological alterations drastically modify
developmental pathways as has been seen in the case of
hypo- and hyperthyroid fetuses in several species including hu-
mans. Therefore, besides the use of nutraceuticals for treating
autistic patients in order to improve their condition, formula-
tion of safe and pro-health preventive nutraceuticals for preg-
nant women and infants is also crucial.
This is an area of research which has to deal with many
constraints such as sample size, sample uniformity, etiopatho-
genic uncertainty of the subjects, and longitudinal designs. As
the trend suggests more ongoing RCTs (Fig. 1, Table 3), future
research is promising for discovering agents to minimize the
symptoms of ASD. Furthermore, there is also a need for ani-
mal studies in many avenues. Especial focus is required in
areas where there exist antagonizing effects of particular nutra-
ceuticals e.g., ﬂavonoids decrease the pathological levels of
interleukin-6 (IL-6), and have been found to produce beneﬁcial
effects in autistic patients. Also, there are reports of their anti-
thyroid effects during fetal development. Scenario, thus, re-
quires research with more paradigmatic strength as autistic
patients are among the most notable clients of nutraceutical
industry.
5. Conclusion
A number of clinical trials with varying designs from open la-
bel to randomized double-blind placebo controlled studies
have been conducted to evaluate the efﬁcacy and safety of di-
verse formulations of nutraceutical agents. However, limita-
tions are overwhelming, and, therefore, conclusive evidence
awaits further research. Taken into consideration, a nutraceu-
tical approach to manage autism still lacks stronger evidence,
though, preliminary evidence is encouraging, but future course
will depend on larger and well-designed studies. A huge gap of
knowledge and utilization of nutraceuticals needs a supervi-
sory role of leading health regulatory ﬁrms like the US Food
and Drug Administration (FDA) in order to conduct better
clinical trials that can provide reliable evidence for the ap-
proval of useful nutraceuticals. So far, we are lucky enough
to have good manufacturing practice guidelines from FDA.
Barriers like lack of proper formulation, administrative resis-
tance and monitoring difﬁculties also need attention of policy
makers.
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